US Army trials augmented reality goggles for dogs

Posted on

The goggles are both a camera and a display
The goggles are both a camera and a display

The US Army has shown off augmented reality goggles for combat dogs, designed to let them receive orders at a distance.

The technology, made by a firm called Command Sight, is managed by the US Army Research Laboratory.

Military dogs can scout ahead for explosives and other hazards, but need instructions.

The goggles are designed to let their handlers direct them, safely out of harm’s way.

In current combat deployments, soldiers usually direct their animals with hand signals or laser pointers – both of which require the handler to be close by.

But that need not be the case if the prototype AR goggles are widely adopted, the army said.

Inside the goggles, the dogs can see a visual indicator that they can be trained to follow, directing them to a specific spot.

The handler, meanwhile, can see what the dog sees through a remote video feed.

“AR will be used to provide dogs with commands and cues; it’s not for the dog to interact with it like a human does,” said Dr Stephen Lee, a senior scientist with the Army Research Laboratory (ARL).

He explained that augmented reality works differently for dogs than for humans, adding: “The military working dog community is very excited about the potential of this technology.”

Each set of goggles is specially fit for each dog, with a visual indictor that allows the dog to be directed to a specific spot and react to the visual cue in the goggles.

The goggles themselves are not new – military dogs are already used to wearing them as protection in bad conditions or for aerial drops, but the augmented reality system is a new development.

Command Sight’s founder Dr AJ Peper said the project was still in its


I saw up close the trials of university life in a pandemic. We should have done better…

Posted on

The trouble with universities is they are both places of teaching, learning and research – and enormous hotels. In the middle of the Covid-19 crisis, they are like stationary cruise ships embedded in nearly all our major cities with tens of thousands of socially active students on board.

Photograph: Peter Byrne/PA

© Provided by The Guardian
Photograph: Peter Byrne/PA

It was inevitable that the arrival of a million students was going to be accompanied by serious outbreaks of coronavirus and so it is proving. But with more realism about what was likely to occur and a greater willingness to take the financial hit, much of what is about to happen could have been avoided.

I write as someone who has just been winched off the bridge of one of the embattled ships. Until the end of August, I was in the thick of it as principal of Hertford College, Oxford, about to step down after nine happy and fulfilling years but in the most surreal of circumstances. Silent corridors, lecture rooms, chapels and bars. A university and college without its students is a forlorn and stranded institution – an academic beehive without its bees.

We were one of the first Oxford colleges to be hit by Covid-19 at the end of the spring term. Very quickly, it became obvious that effective social distancing was barely possible and the only way to contain the outbreak was to disperse the students to their homes as fast as possible, with everyone communicating online via Zoom and Microsoft Teams.

City authorities around the country are discovering they are hosting super-spreaders

Academically, it worked well. Tutors and lecturers had to work extraordinary hours with great dedication to prepare teaching materials to go online. Students hated their isolation, but in terms of learning and teaching we hardly missed a


Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford’s COVID-19 Vaccine Trials are Entering the Final Stage of Development

Posted on

DUBLIN, Oct. 2, 2020 /PRNewswire/ — ResearchAndMarkets.com published a new article on the vaccine industry “COVID-19 Vaccine Trials are Entering the Final Stage of Development”

Research and Markets Logo
Research and Markets Logo

Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the vaccine with 60,000 volunteers from around the world including participants from the US, South Africa, Brazil, Argentina, Columbia, and Chile. Johnson & Johnson’s vaccine joins candidates developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford in beginning the final stage of development.

The company has committed to manufacturing a billion doses of the vaccine on a not for profit basis if proven effective. In contrast to other vaccine candidates that require at least two doses, J&J’s candidate requires just one dose. It also does not require freezing and can remain viable in its liquid form for several months. If the phase 3 trial is successful, both factors could have significant practical advantages for mass vaccination programs.

To see the full article and a list of related reports on the market, visit “COVID-19 Vaccine Trials are Entering the Final Stage of Development”

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716


View original content:http://www.prnewswire.com/news-releases/moderna-pfizer–biontech-and-astrazeneca-and-the-university-of-oxfords-covid-19-vaccine-trials-are-entering-the-final-stage-of-development-301144808.html

SOURCE Research and Markets

Source Article